Literature DB >> 8590922

High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma.

I W Chen1, K J Vastag, J H Lin.   

Abstract

A high-performance liquid chromatographic method coupled with liquid-liquid sample extraction and ultraviolet detection has been developed for the quantification of L-735,524 (I), a potent, highly selective and orally bioavailable inhibitor of recombinant human immunodeficiency virus (HIV) protease in rat, dog and monkey plasma. The present method is reproducible and reliable with limits of quantification of 25, 12.5 and 6.25 ng/ml, respectively for rat, dog and monkey plasma. The standard curve was linear over the range of 6.25-2000 ng/ml in the biological fluid. The mean coefficients of variation for concentration within the range of standard curve were 7.94, 6.91 and 4.52%, respectively, for intra-day analysis and 5.58, 9.27 and 5.45%, respectively, for inter-day analysis. The recoveries of I and L-707,943 (II), an analog of I used as the internal standard, from plasma samples were all over 88% through the extraction procedure. I and II are stable in mobile phase over a 48-h period while waiting for injection at ambient temperature and over a 144-h period in rat, dog and monkey plasma while stored at -20 degrees C. Aqueous solubility of I is pH dependent, 60 mg/ml at pH 3.5 and 0.3 mg/ml at pH 4.8. The analytic procedures described in this report have been successfully employed to quantify the concentration of I in rat, dog and monkey plasma and provide the kinetic information for toxicological and pharmacological studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590922     DOI: 10.1016/0378-4347(95)00191-k

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  8 in total

1.  Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients.

Authors:  P L Carver; D Fleisher; S Y Zhou; D Kaul; P Kazanjian; C Li
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

2.  Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin.

Authors:  Bharat D Damle; Vanaja Mummaneni; Sanjeev Kaul; Catherine Knupp
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Urological management of indinavir-associated acute renal failure in HIV-positive patients.

Authors:  C Kalaitzis; P Passadakis; S Giannakopoulos; S Panagoutsos; E Mpantis; A Triantafyllidis; S Touloupidis; V Vargemezis
Journal:  Int Urol Nephrol       Date:  2006-12-19       Impact factor: 2.370

Review 4.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

5.  Treatment of indinavir sulfate induced urolithiasis in HIV-positive patients.

Authors:  Christos Kalaitzis; Georgios Dimitriadis; Triantafylos Tsatidis; Rainer Kuntz; Stavros Touloupidis; Georgios Kelidis
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 6.  Drug-induced renal calculi: epidemiology, prevention and management.

Authors:  Michel Daudon; Paul Jungers
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs.

Authors:  G Y Kwei; L B Novak; L A Hettrick; E R Reiss; D Ostovic; A E Loper; C Y Lui; R J Higgins; I W Chen; J H Lin
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

8.  Simple, Rapid and Validated LC Determination of Lopinavir in Rat Plasma and its Application in Pharmacokinetic Studies.

Authors:  Rahul Vats; Aditya Narasimha Murthy; Punna Rao Ravi
Journal:  Sci Pharm       Date:  2011-09-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.